These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6759265)

  • 1. Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man.
    Hollander PM; Asplin CM; Palmer JP
    Diabetes; 1982 Jun; 31(6 Pt 1):489-95. PubMed ID: 6759265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
    Ward WK; Bolgiano DC; McKnight B; Halter JB; Porte D
    J Clin Invest; 1984 Oct; 74(4):1318-28. PubMed ID: 6384269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose regulation of glucagon secretion independent of B cell activity.
    Asplin C; Raghu P; Dornan T; Palmer JP
    Metabolism; 1983 Mar; 32(3):292-5. PubMed ID: 6338350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of insulin secretion in diabetes mellitus.
    Ward WK; Beard JC; Halter JB; Porte D
    Adv Exp Med Biol; 1985; 189():137-58. PubMed ID: 3898762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
    Kruszynska YT; Goulas S; Wollen N; McIntyre N
    J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4alpha/MODY1 gene.
    Herman WH; Fajans SS; Smith MJ; Polonsky KS; Bell GI; Halter JB
    Diabetes; 1997 Nov; 46(11):1749-54. PubMed ID: 9356021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of epinephrine on pancreatic beta-cell and alpha-cell function in patients with NIDDM.
    Ortiz-Alonso FJ; Herman WH; Zobel DL; Perry TJ; Smith MJ; Halter JB
    Diabetes; 1991 Sep; 40(9):1194-202. PubMed ID: 1936624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects.
    Palmer JP; Benson JW; Walter RM; Ensinck JW
    J Clin Invest; 1976 Sep; 58(3):565-70. PubMed ID: 783201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose.
    Judzewitsch RG; Pfeifer MA; Best JD; Beard JC; Halter JB; Porte D
    J Clin Endocrinol Metab; 1982 Aug; 55(2):321-8. PubMed ID: 7045153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update.
    Porte D; Kahn SE
    Am J Med; 1991 Jun; 90(6A):8S-14S. PubMed ID: 1872310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus.
    Dimitriadis GD; Pehling GB; Gerich JE
    Diabetes; 1985 Jun; 34(6):541-7. PubMed ID: 3891467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.
    Baron AD; Schaeffer L; Shragg P; Kolterman OG
    Diabetes; 1987 Mar; 36(3):274-83. PubMed ID: 2879757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
    Orskov C; Jeppesen J; Madsbad S; Holst JJ
    J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics.
    McRae JR; Metz SA; Robertson RP
    Metabolism; 1981 Nov; 30(11):1065-75. PubMed ID: 7026970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus.
    Shankar RR; Zhu JS; Baron AD
    Metabolism; 1998 May; 47(5):573-7. PubMed ID: 9591749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B; Larsson H; Holst JJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas.
    Gerich JE; Charles MA; Grodsky GM
    J Clin Invest; 1974 Oct; 54(4):833-41. PubMed ID: 4430717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.